QURE uniQure N.V.
XNAS
24.77
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
QURE
$24.77
—
Key stats
$24.77
- 52-Week Range
- $8.73 – $69.99
- YTD
- +5.92%
- IV Rank (30D)
- 55.0
- Straddle Price
- $6.12
- P/C Vol Ratio
- 0.64
- Market Cap
- $1.8B
- Open
- $25.11
- Day Range
- $23.56 – $25.21
- Volume
- 1,240,758
- Prev Close
- $25.30
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.99% |
| Beta vs SPY | 1.44 |
| Cost of Equity (CAPM) | 11.81% (VRP-adj) |
| WACC | 11.76% |
| Volatility Risk Premium | -12.2pp (IV − HV30), ERP adj -25bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.2B |
| Return on Equity (TTM) | -77.8% |
| Book / Price | 20.9% |
| Gross Margin (TTM) | 92.5% |
| FCF Margin (TTM) | -864.7% |
| Debt / Equity | 0.15 |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $35.04 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $22.77 |
| Bollinger Width / SMA20 | 83.6% (drives anchor stability) |
| Net Debt | $-0.4B |
| Market Cap | $2B |
Peers used for multiples: ARWR, GH, MRNA, NTRA, ROIV, RVMD, TWST, VRTX
60-Day Conviction
79%
20-Day Fair Value
≈ by Nov 30, 2026
$25.12
α +1.2%
rank 86%
conviction
72%
40-Day Fair Value
≈ by Dec 29, 2026
$25.20
α +1.5%
rank 81%
conviction
52%
60-Day Fair Value
≈ by Jan 27, 2027
$25.55
α +3.0%
rank 79%
conviction
79%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $82.11 | 22% | median 15.5× · 7 peers |
| Peer P/S | $7.58 | 22% | median 22.6× · 7 peers |
| Market Anchor (SMA50) | $35.04 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $25.05 | 56% | 44 strikes · skew +0.12 |
As of 2026-10-30 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $1.8B
- Employees
- 221
- List Date
- 2014-02-05
- CIK
- 0001590560
- Next Earnings
- 2026-11-04 (Pre-Market)
- EPS Forecast
- ($0.92)
- Headquarters
- Amsterdam
- Homepage
- https://www.uniqure.com
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -3.67% | -16.05% | -2.70% | -19.77% | -12.80% | -2.86% | -9.64% |
| Feb | 1.94% | -7.11% | -3.14% | 3.42% | -16.51% | -36.72% | -9.69% |
| Mar | -11.46% | 3.38% | -6.41% | -6.98% | -2.75% | 55.71% | 5.25% |
| Apr | -5.39% | -23.19% | -3.86% | -15.36% | 48.94% | 18.12% | 3.21% |
| May | 4.42% | -8.94% | -4.08% | 8.32% | -3.53% | 49.14% | 7.55% |
| Jun | -10.88% | 31.64% | -44.37% | -15.95% | -3.76% | 63.22% | 3.32% |
| Jul | -7.20% | 32.17% | -12.34% | 72.33% | -0.50% | -4.09% | 13.40% |
| Aug | 0.17% | -18.99% | -17.98% | -21.79% | 19.24% | 10.49% | -4.81% |
| Sep | 8.62% | -9.24% | -23.05% | -11.49% | 243.15% | -49.52% | 26.41% |
| Oct | -4.87% | -4.66% | -7.77% | 23.81% | 23.10% | 6.18%* | 5.96% |
| Nov | -12.15% | 40.45% | 17.71% | 1.88% | -19.77% | -- | 5.62% |
| Dec | -21.50% | -13.77% | -5.18% | 147.69% | -9.94% | -- | 19.46% |
| Total | -49.29% | -16.71% | -74.23% | 121.67% | 254.53% | 56.32% | 48.72% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $22.83
SMA 50: $34.55
SMA 200: $29.65
Current: $24.82
EMA 12: $23.94
EMA 26: $26.44
MACD: -2.4996 | Signal: 1.1456
BEARISH
ADX (14): 40.41
STRONG TREND
+DI: 21.75
−DI: 32.22
Momentum Oscillators
RSI (14): 42.39
NEUTRAL
Stoch %K: 87.47
Stoch %D: 86.26
Williams %R: -20.67
Volume & Volatility
BB Upper: $25.16
BB Lower: $20.50
NEUTRAL
OBV: 115,814,535
Vol SMA 20: 1,734,975
Vol ROC: -4.47%
ATR: $1.77
True Range: $1.74
HV 20: 60.5%
HV 30: 148.2%
HV 60: 108.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-31T00:00:00 – 2026-10-29T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (6/10)
Key Drivers:
- Trend direction: Short-term uptrend, Medium-term consolidation
- Support/resistance levels: $43.95 - lower Bollinger Band, $51.36 - upper Bollinger Band
- Momentum signals: Bullish MACD signal, neutral RSI
Primary Risks:
- Negative news sentiment from recent law firm announcements and class action lawsuits
- High implied volatility indicating potential for increased price movement
Investment Thesis:
uniQure (QURE) presents a neutral analysis due to mixed technical and fundamental signals. The short-term uptrend and bullish MACD signal suggest a potential rally, while the consolidation zone and RSI readings indicate caution. Recent negative news headlines from law firms and class action lawsuits may impact sentiment.
Recent News Sentiment Impact:
The recent news headlines have a neutral to slightly bearish impact on sentiment due to negative news related to law firm announcements and class action lawsuits. This sentiment is somewhat mitigated by the positive announcement of the public offering.
Technical Analysis
Trend Direction:
- Short-term: Uptrend
- Medium-term: Consolidation
- Long-term: Neutral
Support/Resistance Levels:
- Lower Bollinger Band: $43.95
- Upper Bollinger Band: $51.36
Momentum Signals:
- RSI (14): 43.70 (neutral)
- MACD signal: Bullish
- Bollinger Bands position: Squeeze
Volume Analysis:
- Volume SMA 20: 1110857.73
- On-Balance Volume (OBV): 161789627.79
- Volume Rate of Change: 47.11%
News & Sentiment Analysis
Recent Headlines Summary:
- Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound? (Zacks Investment Research, 2026-09-03)
- Sentiment: NEUTRAL
- uniQure Announces Pricing of Upsized $225 Million Public Offering (GlobeNewswire Inc., 2026-06-24)
- Sentiment: POSITIVE
- Numero AI and Royu Merge to Redefine How Finance Teams Operate (Benzinga, 2026-05-21)
- Sentiment: NEUTRAL
- QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm (GlobeNewswire Inc., 2026-04-13)
- Sentiment: NEGATIVE
- INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens Berman (GlobeNewswire Inc., 2026-04-10)
- Sentiment: NEGATIVE
Sentiment Assessment:
- Aggregate news sentiment: NEUTRAL
- Catalyst Identification:
- Upcoming events: Earnings reports, product launches
- Regulatory changes: FDA approvals, clinical trial updates
Market Narrative:
The recent negative news headlines have a neutral to slightly bearish impact on sentiment. The positive public offering announcement somewhat offsets the negative sentiment.
Risk & Volatility Assessment
Beta Interpretation:
- Risk relative to market (beta): -0.30 (vs SPY)
- Alpha: 3.14
Volatility Regime:
- Current vs historical volatility levels: Higher than average
- Options Market Signals:
- IV Rank: 44.9% (Medium)
- Current IV: 154.0%
- Expected Move: $13.25 (42 DTE), 7-DTE: $7.10
Downside Protection:
- Support levels and risk management considerations: The lower Bollinger Band at $43.95 provides a potential support level.
Market Context & Positioning
Sector Performance:
- Relative strength vs sector/market: Neutral
Institutional Activity:
- Volume patterns suggesting institutional interest: Moderate institutional buying
Correlation Analysis:
- How stock moves relative to market (R-squared interpretation): Weakly correlated with the market
Relative Valuation:
- Position within trading range: Consolidation zone
Key Levels & Action Items
Critical Price Levels:
- Support/resistance levels: $43.95 - lower Bollinger Band, $51.36 - upper Bollinger Band
Breakout/Breakdown Levels:
- Technical levels that could trigger significant moves: The upper and lower Bollinger Bands
Time-Sensitive Catalysts:
- Earnings reports, product launches, FDA approvals, clinical trial updates
Risk Management:
- Stop-loss levels and position sizing considerations: Consider setting a stop-loss at $43.95 to limit potential losses.
Please note that this analysis is based on the provided data and should be considered as a starting point for further research.
Generated
News
All QURE news →
Earnings History
21 of 23 under expected move
Avg Expected Move
15.79%
Avg Actual Move
5.86%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-01 | Pre-Market | 16.24% | 3.68% | 0.23x | Within |
| 2021-05-10 | Pre-Market | 13.82% | 0.92% | 0.07x | Within |
| 2021-07-27 | Pre-Market | 15.99% | 4.52% | 0.28x | Within |
| 2021-10-25 | Pre-Market | 11.95% | 3.16% | 0.26x | Within |
| 2022-02-28 | Pre-Market | 7.71% | 0.71% | 0.09x | Within |
| 2022-05-02 | Pre-Market | 16.73% | 5.56% | 0.33x | Within |
| 2022-08-08 | Pre-Market | 13.70% | 27.02% | 1.97x | Exceeded |
| 2022-11-02 | Pre-Market | 5.57% | 7.27% | 1.31x | Exceeded |
| 2023-02-27 | Pre-Market | 14.03% | 5.21% | 0.37x | Within |
| 2023-05-09 | Pre-Market | 13.41% | 0.79% | 0.06x | Within |
| 2023-08-01 | Pre-Market | 10.13% | 2.41% | 0.24x | Within |
| 2023-11-07 | Pre-Market | 13.58% | 12.68% | 0.93x | Within |
| 2024-02-28 | Pre-Market | 16.74% | 0.89% | 0.05x | Within |
| 2024-05-07 | Pre-Market | 12.71% | 2.12% | 0.17x | Within |
| 2024-08-01 | Pre-Market | 15.34% | 2.35% | 0.15x | Within |
| 2024-11-05 | Pre-Market | 16.64% | 8.99% | 0.54x | Within |
| 2025-02-27 | Pre-Market | 16.71% | 3.43% | 0.21x | Within |
| 2025-05-09 | After-Close | 11.73% | 2.81% | 0.24x | Within |
| 2025-07-29 | Pre-Market | 17.69% | 8.68% | 0.49x | Within |
| 2025-11-10 | Pre-Market | 22.40% | 5.90% | 0.26x | Within |
| 2026-03-02 | After-Close | 39.52% | 14.00% | 0.35x | Within |
| 2026-05-05 | Pre-Market | 17.89% | 2.32% | 0.13x | Within |
| 2026-07-29 | Pre-Market | 22.98% | 9.30% | 0.40x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
QURE Options Activity & IV Rank
QURE IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 120.1%
7-DTE IV: 127.9%
Expected Move: $6.12
7-DTE Move: $6.12
Days to Exp: 21 (2026-11-20)
Options Flow
Call Volume: 1,819
Put Volume: 1,160
P/C Volume: 0.638
BULLISH
Call OI: 27,816
Put OI: 13,122
P/C OI: 0.472
Total OI: 40,938
ATM Options Pricing
ATM Call: $3.00
ATM Put: $3.12
Call %: 12.1%
Put %: 12.6%
Chain Summary
Chain Volume: 10,340
Chain OI: 188,051
Last Updated: 10/30/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 66th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
66%
vs own history
GEX tilt
+0.38
OI-weighted, today
Vanna tilt
+0.12
δ-sensitivity to IV
Charm tilt
-0.20
δ-decay vs time
? What is this?
· 39 ATM contracts, 12k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)52.1MediumOct 30
IV Rank (30 DTE)55.0MediumOct 30
Straddle Price (30 DTE)$6.12Oct 30
Beta Analysis
Risk Metrics
Beta: 0.3304
Alpha: -3.59%
Correlation: 0.0297
R-Squared: 0.1%
Stock Volatility: 142.9%
Market Volatility: 12.9%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own QURE
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $41.9M | #783 of 6285 | +125.0% | 13F | |
| Point72 Hedge fund Steve Cohen | $27.9M | #486 of 1945 | new | 13F | |
| Millennium Management Hedge fund Izzy Englander | $15.8M | #1278 of 3716 | -56.7% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $9K | #4036 of 4729 | +1371.4% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
QURE Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 61,251,302 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
29 filers$1.37B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $356.19M | 26.00% | 2026-06-30 |
| 2 | Caption Management, LLC | $224.90M | 16.42% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $138.21M | 10.09% | 2026-06-30 |
| 4 | Nantahala Capital Management, LLC | $110.54M | 8.07% | 2026-06-30 |
| 5 | Citigroup Inc. Custodian | $91.89M | 6.71% | 2026-06-30 |
| 6 | TUDOR INVESTMENT CORP ET AL | $75.76M | 5.53% | 2026-06-30 |
| 7 | Jane Street Group, LLC Custodian | $75.70M | 5.53% | 2026-06-30 |
| 8 | 683 Capital Management, LLC | $43.69M | 3.19% | 2026-06-30 |
| 9 | DIADEMA PARTNERS LP | $32.53M | 2.37% | 2026-06-30 |
| 10 | FourWorld Capital Management LLC | $30.40M | 2.22% | 2026-06-30 |
| 11 | Affinity Asset Advisors, LLC | $27.64M | 2.02% | 2026-06-30 |
| 12 | Millennium Management LLC Custodian | $27.61M | 2.02% | 2026-06-30 |
| 13 | Barclays PLC Custodian | $26.06M | 1.90% | 2026-06-30 |
| 14 | LMR Partners LLP | $20.73M | 1.51% | 2026-06-30 |
| 15 | Wolverine Trading, LLC Custodian | $19.80M | 1.45% | 2025-09-30 |
| 16 | SIG BROKERAGE, LP | $17.62M | 1.29% | 2026-06-30 |
| 17 | PEAK6 LLC | $11.16M | 0.81% | 2026-06-30 |
| 18 | BOOTHBAY FUND MANAGEMENT, LLC | $10.68M | 0.78% | 2026-06-30 |
| 19 | Creek Drive Management Group LLC | $6.91M | 0.50% | 2026-06-30 |
| 20 | K2 PRINCIPAL FUND, L.P. | $6.91M | 0.50% | 2026-06-30 |
| 21 | Persistent Asset Partners Ltd | $2.95M | 0.22% | 2026-06-30 |
| 22 | Centiva Capital, LP | $2.81M | 0.20% | 2026-06-30 |
| 23 | NOMURA HOLDINGS INC | $2.79M | 0.20% | 2026-06-30 |
| 24 | Shay Capital LLC | $2.49M | 0.18% | 2026-06-30 |
| 25 | Palogic Value Management, L.P. | $2.42M | 0.18% | 2026-06-30 |
16 filers$307.46M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $82.45M | 26.82% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $58.05M | 18.88% | 2026-06-30 |
| 3 | DIADEMA PARTNERS LP | $41.32M | 13.44% | 2026-06-30 |
| 4 | TUDOR INVESTMENT CORP ET AL | $28.19M | 9.17% | 2026-06-30 |
| 5 | Caption Management, LLC | $27.79M | 9.04% | 2026-06-30 |
| 6 | Nantahala Capital Management, LLC | $22.32M | 7.26% | 2026-06-30 |
| 7 | Wolverine Trading, LLC Custodian | $16.45M | 5.35% | 2025-09-30 |
| 8 | Jane Street Group, LLC Custodian | $12.63M | 4.11% | 2026-06-30 |
| 9 | LMR Partners LLP | $6.55M | 2.13% | 2026-06-30 |
| 10 | Barclays PLC Custodian | $4.84M | 1.57% | 2026-06-30 |
| 11 | Citigroup Inc. Custodian | $2.90M | 0.94% | 2026-06-30 |
| 12 | Walleye Capital LLC | $1.99M | 0.65% | 2026-06-30 |
| 13 | Verition Fund Management LLC | $829.08K | 0.27% | 2026-06-30 |
| 14 | SIG BROKERAGE, LP | $690.90K | 0.22% | 2026-06-30 |
| 15 | Walleye Trading LLC | $345.45K | 0.11% | 2026-06-30 |
| 16 | Persistent Asset Partners Ltd | $133.87K | 0.04% | 2026-06-30 |
QURE Insider Trading (Form 4)
Latest: 2026-07-07Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-07 | Matthew C Kapusta | CEO, Managing Director | Mixed | — | $32.27 | -$543.3K | EDGAR |
| 2026-07-02 | Jack Kaye | Director | Mixed | — | $34.94 | -$486.8K | EDGAR |
| 2026-07-02 | Walid Abi-Saab | Chief Medical Officer | Mixed | −20,000 | $36.21 | -$1.34M | EDGAR |
| 2026-06-26 | Matthew C Kapusta | CEO, Managing Director | Mixed | −2,568 | $41.21 | -$729.7K | EDGAR |
| 2026-06-22 | Madhavan Balachandran | Director | Mixed | — | $35.01 | -$234.7K | EDGAR |
| 2026-06-22 | Matthew C Kapusta | CEO, Managing Director | Mixed | −138,863 | $39.27 | -$8.01M | EDGAR |
| 2026-06-22 | Jack Kaye | Director | Mixed | — | $37.14 | -$57.5K | EDGAR |
| 2026-06-17 | Jeannette Potts | Chief Legal Officer | Sell (S) | −5,237 | $27.67 | -$144.9K | EDGAR |
| 2026-06-17 | Madhavan Balachandran | Director | Mixed | — | $18.17 | -$193.6K | EDGAR |
| 2026-06-12 | Kylie O'Keefe | Chief Customer & Strat Officer | Sell (S) | −15,936 | $27.06 | -$431.2K | EDGAR |
| 2026-06-12 | Rachelle Suzanne Jacques | Director | Mixed | +5,557 | $27.06 | -$53.9K | EDGAR |
| 2026-06-12 | Jack Kaye | Director | Mixed | +5,557 | $27.06 | -$53.9K | EDGAR |
| 2026-06-12 | Leonard E Post | Director | Mixed | +5,557 | $27.06 | -$53.9K | EDGAR |
| 2026-06-12 | David D. Meek | Director | Mixed | +5,557 | $27.06 | -$53.9K | EDGAR |
| 2026-06-12 | Robert Gut | Director | Mixed | −83 | $24.21 | -$228.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
QURE Insider Holdings
12 insiders · @ $24.82
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Matthew C Kapusta | CEO, Managing Director | 519,227 | $12.89M | -$50.18M | 69 | 2026-07-07 |
| 2 | Christian Klemt | Chief Financial Officer | 226,581 | $5.62M | -$4.79M | 38 | 2026-03-06 |
| 3 | Walid Abi-Saab | Chief Medical Officer | 178,235 | $4.42M | -$2.58M | 8 | 2026-07-02 |
| 4 | Jeannette Potts | Chief Legal Officer | 133,246 | $3.31M | -$428.5K | 8 | 2026-06-17 |
| 5 | Kylie O'Keefe | Chief Customer & Strat Officer | 108,864 | $2.70M | -$431.2K | 2 | 2026-06-12 |
| 6 | Madhavan Balachandran | Director | 43,254 | $1.07M | -$1.07M | 20 | 2026-06-22 |
| 7 | Jeremy P. Springhorn | Director | 43,251 | $1.07M | -$263.9K | 18 | 2026-06-12 |
| 8 | Jack Kaye | Director | 43,056 | $1.07M | -$2.96M | 24 | 2026-07-02 |
| 9 | David D. Meek | Director | 41,740 | $1.04M | -$220.6K | 16 | 2026-06-12 |
| 10 | Rachelle Suzanne Jacques | Director | 35,896 | $890.9K | -$146.7K | 10 | 2026-06-12 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
QURE Board & Officers
As of SEC filings through Jul 7, 2026Directors 8
- Jack Kaye · since Jan 1, 2017
- Matthew C Kapusta · since Jan 1, 2017
- Jeremy P. Springhorn · since Sep 14, 2017
- Madhavan Balachandran · since Sep 14, 2017
- David D. Meek · since Jun 13, 2018
- Robert Gut · listed since Jan 2020
- Leonard E Post · since Jun 17, 2020
- Rachelle Suzanne Jacques · since Oct 21, 2021
Officers 5
- Matthew C Kapusta · CEO, Managing Director · listed since Feb 2022
- Christian Klemt · Chief Financial Officer · listed since Jun 2021
- Walid Abi-Saab · Chief Medical Officer · since Sep 27, 2023
- Jeannette Potts · Chief Legal Officer · listed since Mar 2024
- Kylie O'Keefe · Chief Customer & Strat Officer · since Feb 25, 2026
Changes in the last 10 years (47)
| Feb 25, 2026 | Kylie O'Keefe became Chief Customer & Strat Officer |
| Jul 22, 2024 | The company announced the departure of Pierre Caloz as Chief Operating Officer in an SEC filing |
| Apr 9, 2024 | The company announced the departure of Paula Soteropoulos from the board in an SEC filing |
| Mar 5, 2024 | Jeannette Potts listed as Chief Legal Officer (previously Chief Legal and Compliance Officer) in SEC filings |
| Oct 5, 2023 | The company announced the departure of Ricardo Dolmetsch as President, R&D in an SEC filing |
| Sep 27, 2023 | Walid Abi-Saab became Chief Medical Officer |
| Jun 13, 2023 | Jeannette Potts became Chief Legal and Compliance Officer |
| Feb 28, 2022 | Matthew C Kapusta listed as CEO, Managing Director (previously CEO, CFO, Managing Director) in SEC filings |
| Oct 21, 2021 | Rachelle Suzanne Jacques became a director |
| Jun 17, 2021 | Christian Klemt listed as Chief Financial Officer (previously Chief Accounting Officer) in SEC filings |
| Jun 15, 2021 | Pierre Caloz became Chief Operating Officer |
| Mar 1, 2021 | Robert Gut no longer listed as Chief Medical Officer in SEC filings |
| Mar 1, 2021 | Ricardo Dolmetsch listed as President, R&D (previously President) in SEC filings |
| Sep 15, 2020 | Ricardo Dolmetsch became President |
| Jun 17, 2020 | Leonard E Post became a director |
| Jan 31, 2020 | Robert Gut first listed as a director in an SEC filing |
| Sep 20, 2019 | Robert Gut no longer listed as a director in SEC filings |
| Sep 19, 2019 | Sander van Deventer listed as EVP, Research & Product Dev. (previously Chief Scientific Officer) in SEC filings |
| Aug 30, 2019 | Alexander Edward Kuta III listed as Executive VP, Operations (previously SVP, Regulatory Affairs) in SEC filings |
| Sep 25, 2018 | Robert Gut first listed as Chief Medical Officer in an SEC filing |
| Jun 13, 2018 | Robert Gut became a director |
| Jun 13, 2018 | David D. Meek became a director |
| Apr 23, 2018 | Forbion 1 Management B.V. became a 10% owner |
| Apr 23, 2018 | ForUniqure B.V. became a 10% owner |
| Jan 30, 2018 | Alexander Edward Kuta III listed as SVP, Regulatory Affairs (previously Sr VP of Regulatory Affairs) in SEC filings |
| Jan 3, 2018 | Maria E Cantor first listed as SVP, Investor Relations & Comm in an SEC filing |
| Sep 22, 2017 | Sander van Deventer no longer listed as a director in SEC filings |
| Sep 22, 2017 | Sander van Deventer first listed as Chief Scientific Officer in an SEC filing |
| Sep 14, 2017 | Madhavan Balachandran became a director |
| Sep 14, 2017 | Jeremy P. Springhorn became a director |
| Aug 7, 2017 | Scott T. McMillan became Chief Operating Officer |
| Aug 7, 2017 | Christian Klemt became Chief Accounting Officer |
| Jun 5, 2017 | Steven Zelenkofske became Chief Medical Officer |
| Jan 23, 2017 | Alexander Edward Kuta III became Sr VP of Regulatory Affairs |
| Jan 1, 2017 | William Lewis became a director |
| Jan 1, 2017 | Sander van Deventer became a director |
| Jan 1, 2017 | Philip Astley-Sparke became a director |
| Jan 1, 2017 | Paula Soteropoulos became a director |
| Jan 1, 2017 | Paul E Firuta became Chief Commercial Officer |
| Jan 1, 2017 | Matthew C Kapusta became a director |
| Jan 1, 2017 | Matthew C Kapusta became CEO, CFO, Managing Director |
| Jan 1, 2017 | Maiken Keson-Brookes became General Counsel |
| Jan 1, 2017 | Jonathan Garen became Chief Business Officer |
| Jan 1, 2017 | Jack Kaye became a director |
| Jan 1, 2017 | Harald Petry became Chief Scientific Officer |
| Jan 1, 2017 | David Schaffer became a director |
| Jan 1, 2017 | Christian Meyer became Chief Medical Officer |
Not reported recently (15)
- Alexander Edward Kuta III · Last reported as Executive VP, Operations in an SEC filing dated Mar 9, 2023
- Philip Astley-Sparke · Last reported as a director in an SEC filing dated Mar 4, 2021
- David Schaffer · Last reported as a director in an SEC filing dated Mar 2, 2020
- Sander van Deventer · Last reported as EVP, Research & Product Dev. in an SEC filing dated Mar 2, 2020
- Scott T. McMillan · Last reported as Chief Operating Officer in an SEC filing dated Jan 30, 2019
- Steven Zelenkofske · Last reported as Chief Medical Officer in an SEC filing dated Jun 8, 2018
- ForUniqure B.V. · Last reported as a 10% owner in an SEC filing dated May 16, 2018
- Forbion 1 Management B.V. · Last reported as a 10% owner in an SEC filing dated May 16, 2018
- Maria E Cantor · Last reported as SVP, Investor Relations & Comm in an SEC filing dated Jan 30, 2018
- Jonathan Garen · Last reported as Chief Business Officer in an SEC filing dated Jan 30, 2018
- Paul E Firuta · Last reported as Chief Commercial Officer in an SEC filing dated Jan 30, 2018
- Harald Petry · Last reported as Chief Scientific Officer in an SEC filing dated Jun 29, 2017
- Maiken Keson-Brookes · Last reported as General Counsel in an SEC filing dated Feb 21, 2017
- Christian Meyer · Last reported as Chief Medical Officer in an SEC filing dated Feb 21, 2017
- William Lewis · Last reported as a director in an SEC filing dated Jan 31, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
QURE Proposed Insider Sales (Form 144)
Latest: 2026-07-02
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-07-02 | Kapusta Matthew C | Officer, Director, CEO AND MANAGING DIRECTOR | 21,082 | $951.9K | 2026-07-02 | CITIGROUP GLOBAL MARKETS | 10b5-1 | EDGAR |
| 2026-06-30 | Abi-Saab Walid | Chief Medical Officer | 30,000 | $1.39M | 2026-06-30 | Citigroup Global Markets, Inc | 10b5-1 | EDGAR |
| 2026-06-30 | Kaye Jack | Director | 21,167 | $983.0K | 2026-06-30 | Citigroup Global Markets, Inc | 10b5-1 | EDGAR |
| 2026-06-26 | Abi-Saab Walid | Chief Medical Officer | 1,434 | $67.2K | 2026-06-26 | Citigroup Global Markets, Inc | — | EDGAR |
| 2026-06-25 | Kapusta Matthew C | Officer, Director, CEO AND MANAGING DIRECTOR | 28,716 | $1.44M | 2026-06-25 | CITIGROUP GLOBAL MARKETS | 10b5-1 | EDGAR |
| 2026-06-24 | Kapusta Matthew C | Officer, Director, CEO AND MANAGING DIRECTOR | 6,696 | $334.8K | 2026-06-24 | CITIGROUP GLOBAL MARKETS | 10b5-1 | EDGAR |
| 2026-06-18 | Kapusta Matthew C | Officer, Director, CEO AND MANAGING DIRECTOR | 41,671 | $1.93M | 2026-06-18 | CITIGROUP GLOBAL MARKETS | 10b5-1 | EDGAR |
| 2026-06-17 | Kapusta Matthew C | Officer, Director, CEO AND MANAGING DIRECTOR | 164,429 | $7.07M | 2026-06-17 | CITIGROUP GLOBAL MARKETS | 10b5-1 | EDGAR |
| 2026-06-17 | Kaye Jack | Director | 5,295 | $225.4K | 2026-06-17 | Citigroup Global Markets, Inc | 10b5-1 | EDGAR |
| 2026-06-17 | Balachandran Madhavan | Director | 11,685 | $526.5K | 2026-06-17 | Citigroup Global Markets, Inc | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
24 ETFs hold QURE
24 shown · $113.90M total exposure · 0.05% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.49% | $53.4M | $10.8B | 2026-10-28 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.02% | $18.9M | — | 2026-09-30 |
| 3 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.11% | $12.6M | $11.5B | 2026-10-28 |
| 4 | JGRO JPMorgan Active Growth ETF | JPMorgan | 0.11% | $10.5M | $9.8B | 2026-10-29 |
| 5 | VHT Vanguard Health Care ETF | Vanguard | 0.02% | $3.8M | — | 2026-09-30 |
| 6 | PTH Invesco Dorsey Wright Healthcare Momentum ETF | Nport | 1.50% | $3.5M | — | 2026-07-31 |
| 7 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $2.2M | $97.2B | 2026-10-28 |
| 8 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.33% | $2.2M | — | 2026-10-29 |
| 9 | KOMP State Street® SPDR® S&P Kensho New Economies Composite ETF | SPDR (State Street) | 0.09% | $2.2M | $2.6B | 2026-10-28 |
| 10 | GNOM Global X Genomics & Biotechnology ETF | Global X | 0.97% | $1.1M | — | 2026-10-29 |
| 11 | ESML iShares ESG Aware MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.03% | $728,700 | $2.8B | 2026-10-28 |
| 12 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.02% | $652,117 | $3.8B | 2026-10-28 |
| 13 | BBSC JPMorgan BetaBuilders U.S. Small Cap Equity ETF | JPMorgan | 0.07% | $497,803 | $751.2M | 2026-10-29 |
| 14 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.00% | $439,322 | $10.9B | 2026-10-28 |
| 15 | ISCV iShares Morningstar Small-Cap Value ETF | iShares (BlackRock) | 0.05% | $361,790 | $694.5M | 2026-10-28 |
| 16 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.01% | $230,373 | $4.3B | 2026-10-28 |
| 17 | IBBQ Invesco Nasdaq Biotechnology ETF | Invesco | 0.11% | $132,890 | — | 2026-10-28 |
| 18 | GINN Goldman Sachs Innovate Equity ETF | Goldman | 0.05% | $96,359 | $178.7M | 2026-10-28 |
| 19 | BIB ProShares Ultra NASDAQ Biotechnology | ProShares | 0.07% | $69,192 | — | 2026-10-28 |
| 20 | WSML iShares MSCI World Small-Cap ETF | iShares (BlackRock) | 0.01% | $67,019 | $668.8M | 2026-10-28 |
| 21 | MSML iShares MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.02% | $54,834 | $279.4M | 2026-10-28 |
| 22 | SPGM State Street® SPDR® Portfolio MSCI Global Stock Market ETF | SPDR (State Street) | 0.00% | $13,457 | $1.8B | 2026-10-28 |
| 23 | GNMX Corgi Genomics & Precision Medicine ETF | Corgi | 0.87% | $12,043 | $1.4M | 2026-10-29 |
| 24 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.00% | $1,298 | $3.2B | 2026-10-28 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-4.01
TTM Revenue
$18.67M
TTM Net Income
$-252.21M
TTM Op. Cash Flow
$-160.79M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $5.84M | $-81.06M | $-1.22 | $-28.58M |
| Q1 '26 | 2026-03-31 | $3.56M | $-53.53M | $-0.85 | $-38.24M |
| Q4 '25 | 2025-12-31 | $5.57M | $-37.09M | $-0.56 | $-77.57M |
| Q3 '25 | 2025-09-30 | $3.70M | $-80.53M | $-1.38 | $-16.40M |
| Q2 '25 | 2025-06-30 | $5.26M | $-37.72M | $-0.69 | $-39.90M |
| Q1 '25 | 2025-03-31 | $1.57M | $-43.64M | $-0.82 | $-44.10M |
| Q4 '24 | 2024-12-31 | $5.22M | $-73.26M | $-1.50 | $-52.84M |
| Q3 '24 | 2024-09-30 | $2.29M | $-44.38M | $-0.91 | $-36.60M |
| Q2 '24 | 2024-06-30 | $11.13M | $-56.30M | $-1.16 | $-32.71M |
| Q1 '24 | 2024-03-31 | $8.48M | $-65.62M | $-1.36 | $-60.58M |
| Q4 '23 | 2023-12-31 | $6.69M | $-73.21M | $-1.53 | $-49.54M |
| Q3 '23 | 2023-09-30 | $1.41M | $-89.57M | $-1.88 | $40.12M |
Q2 2026 • period ending 2026-06-30 • filed 2026-07-29
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
4.69
P/S
81.40
EV/EBITDA
—
EV/Sales
61.97
ROE
-77.8%
ROA
-25.6%
Div Yield
0.00%
FCF Yield
-10.58%
Debt/Equity
0.15
Current Ratio
—
Market Cap
$1.52B
as of 2026-10-30
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
8.72M
SI % of Float
13.18%
Days to Cover
1.94
Short Vol Ratio
24.9%
Free Float
66.14M
Float %
95.4%
Short interest 2026-09-30 • Short volume 2026-10-29 • Float 2026-08-24